tbuckley/cabot-search huggingface dataset:
TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma
Authors: Philippe Moreau, Leona Holmberg, Nathalie Meuleman, Philippa Graham, Olivier De Henau, Gregory Driessens, Yvonne McGrath, Joanne Lager, Geoffrey R Hill
Journal: Blood (2021)
Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline <i>BCR-ABL1</i> Level and Baseline Mutation Status in the Optic Trial
Authors: Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues De Lavallade, Jeffrey H. Lipton, Elza Lomaia, James K McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Soledad S. Undurraga, Vickie Lu, Alexander Vorog, Jorge E. Cortes
Journal: Blood (2021)
Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
Authors: Hossein Sendi, Mostafa Yazdimamaghani, Mengying Hu, Nikhila Sultanpuram, Jie Wang, Amber S. Moody, Ellie McCabe, Jiajie Zhang, Amanda Graboski, Liantao Li, Juan D. Rojas, Paul A. Dayton, Leaf Huang, Andrew Z. Wang
Journal: Cancer Research (2021)

Abstract Liver metastasis is a leading cause of cancer morbidity and mortality. Thus, there has been strong interest in the development of therapeutics that can effectively prevent liver metastasis. One potential strategy is to utilize molecules that have broad effects on the liver microenvironment, such as miR-122, a liver-specific miRNA that is a key regulator of diverse hepatic functions. Here we report the development of a nanoformulation miR-122 as a therapeutic agent for preventing liver metastasis. We engineered a galactose-targeted lipid calcium phosphate (Gal-LCP) nanoformulation of miR-122. This nanotherapeutic elicited no significant toxicity and delivered miR-122 into hepatocytes with specificity and high efficiency. Across multiple colorectal cancer liver metastasis models, treatment with Gal-LCP miR-122 treatment effectively prevented colorectal cancer liver metastasis and prolonged survival. Mechanistic studies revealed that delivery of miR-122 was associated with downregulation of key genes involved in metastatic and cancer inflammation pathways, including several proinflammatory factors, matrix metalloproteinases, and other extracellular matrix degradation enzymes. Moreover, Gal-LCP miR-122 treatment was associated with an increased CD8+/CD4+ T-cell ratio and decreased immunosuppressive cell infiltration, which makes the liver more conducive to antitumor immune response. Collectively, this work presents a strategy to improve cancer prevention and treatment with nanomedicine-based delivery of miRNA. Significance: Highly specific and efficient delivery of miRNA to hepatocytes using nanomedicine has therapeutic potential for the prevention and treatment of colorectal cancer liver metastasis.
Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer
Authors: Ying Ye, Weiyi Feng, Jialiang Zhang, Kaiyu Zhu, Xudong Huang, Ling Pan, Jiachun Su, Yanfen Zheng, Rui Li, Shuang Deng, Ruihong Bai, Lisha Zhuang, Lusheng Wei, Junge Deng, Mei Li, Rufu Chen, Dongxin Lin, Zhixiang Zuo, Jian Zheng
Journal: Genome Medicine (2021)

N6-methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells and play critical roles in cancer. While most related studies focus on m6A modifications in linear RNA, transcriptome-wide profiling and exploration of m6A modification in circular RNAs in cancer is still lacking.For the detection of m6A modification in circRNAs, we developed a new bioinformatics tools called Circm6A and applied it to the m6A-seq data of 77 tissue samples from 58 individuals with pancreatic ductal adenocarcinoma (PDAC).Circm6A performs better than the existing circRNA identification tools, which achieved highest F1 score among these tools in the detection of circRNAs with m6A modifications. By using Circm6A, we identified a total of 8807 m6A-circRNAs from our m6A-seq data. The m6A-circRNAs tend to be hypermethylated in PDAC tumor tissues compared with normal tissues. The hypermethylated m6A-circRNAs were associated with a significant gain of circRNA-mRNA coexpression network, leading to the dysregulation of many important cancer-related pathways. Moreover, we found the cues that hypermethylated m6A-circRNAs may promote the circularization and translation of circRNAs.These comprehensive findings further bridged the knowledge gaps between m6A modification and circRNAs fields by depicting the m6A-circRNAs genomic landscape of PDAC patients and revealed the emerging roles played by m6A-circRNAs in pancreatic cancer. Circm6A is available at https://github.com/canceromics/circm6a .
Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia Enrolled in Phase 3 Studies
Authors: Janet L. Kwiatkowski, Franco Locatelli, Mark C. Walters, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Richard A. Colvin, Katiana Gruppioni, Alexis A. Thompson
Journal: Blood (2021)
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Authors: Jun J. Mao, Geetha Gopalakrishna Pillai, Carlos Jose Andrade, Jennifer A. Ligibel, Partha Basu, Lorenzo Cohen, Ikhlas A. Khan, Karen M. Mustian, Rammanohar Puthiyedath, Kartar Singh Dhiman, Lixing Lao, Ricardo Ghelman, Paulo Cáceres Guido, Gabriel Lopez, Daniel F. Gallego‐Perez, Luis Alejandro Salicrup
Journal: CA A Cancer Journal for Clinicians (2021)

Abstract The increase in cancer incidence and mortality is challenging current cancer care delivery globally, disproportionally affecting low‐ and middle‐income countries (LMICs) when it comes to receiving evidence‐based cancer prevention, treatment, and palliative and survivorship care. Patients in LMICs often rely on traditional, complementary, and integrative medicine (TCIM) that is more familiar, less costly, and widely available. However, spheres of influence and tensions between conventional medicine and TCIM can further disrupt efforts in evidence‐based cancer care. Integrative oncology provides a framework to research and integrate safe, effective TCIM alongside conventional cancer treatment and can help bridge health care gaps in delivering evidence‐informed, patient‐centered care. This growing field uses lifestyle modifications, mind and body therapies (eg, acupuncture, massage, meditation, and yoga), and natural products to improve symptom management and quality of life among patients with cancer. On the basis of this review of the global challenges of cancer control and the current status of integrative oncology, the authors recommend: 1) educating and integrating TCIM providers into the cancer control workforce to promote risk reduction and culturally salient healthy life styles; 2) developing and testing TCIM interventions to address cancer symptoms or treatment‐related adverse effects (eg, pain, insomnia, fatigue); and 3) disseminating and implementing evidence‐based TCIM interventions as part of comprehensive palliative and survivorship care so patients from all cultures can live with or beyond cancer with respect, dignity, and vitality. With conventional medicine and TCIM united under a cohesive framework, integrative oncology may provide citizens of the world with access to safe, effective, evidence‐informed, and culturally sensitive cancer care.
Patient-Reported Factors Associated With Older Adults’ Cancer Screening Decision-making
Authors: Jenna Smith, Rachael H. Dodd, Karen M. Gainey, Vasi Naganathan, Erin Cvejic, Jesse Jansen, Kirsten J. McCaffery
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Decisions for older adults (aged ≥65 years) and their clinicians about whether to continue to screen for cancer are not easy. Many older adults who are frail or have limited life expectancy or comorbidities continue to be screened for cancer despite guidelines suggesting they should not; furthermore, many older adults have limited knowledge of the potential harms of continuing to be screened. <h3>Objective</h3> To summarize the patient-reported factors associated with older adults’ decisions regarding screening for breast, prostate, colorectal, and cervical cancer. <h3>Evidence Review</h3> Studies were identified by searching databases from January 2000 to June 2020 and were independently assessed for inclusion by 2 authors. Data extraction and risk of bias assessment were independently conducted by 2 authors, and then all decisions were cross-checked and discussed where necessary. Data analysis was performed from September to December 2020. <h3>Findings</h3> The search yielded 2475 records, of which 21 unique studies were included. Nine studies were quantitative, 8 were qualitative, and 4 used mixed method designs. Of the 21 studies, 17 were conducted in the US, and 10 of 21 assessed breast cancer screening decisions only. Factors associated with decision-making were synthesized into 5 categories: demographic, health and clinical, psychological, physician, and social and system. Commonly identified factors associated with the decision to undergo screening included personal or family history of cancer, positive screening attitudes, routine or habit, to gain knowledge, friends, and a physician’s recommendation. Factors associated with the decision to forgo screening included being older, negative screening attitudes, and desire not to know about cancer. Some factors had varying associations, including insurance coverage, living in a nursing home, prior screening experience, health problems, limited life expectancy, perceived cancer risk, risks of screening, family, and a physician’s recommendation to stop. <h3>Conclusions and Relevance</h3> Although guidelines suggest incorporating life expectancy and health status to inform older adults’ cancer screening decisions, older adults’ ingrained beliefs about screening may run counter to these concepts. Communication strategies are needed that support older adults to make informed cancer screening decisions by addressing underlying screening beliefs in context with their perceived and actual risk of developing cancer.
Association of Maternal Stress and Social Support During Pregnancy With Growth Marks in Children’s Primary Tooth Enamel
Authors: Rebecca V. Mountain, Yiwen Zhu, Olivia R. Pickett, Alexandre A. Lussier, Jill M. Goldstein, Joshua L. Roffman, Felicitas B. Bidlack, Erin C. Dunn
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Exposure to maternal psychosocial stressors during the prenatal and perinatal periods can have major long-term mental health consequences for children. However, valid and inexpensive biomarkers are currently unavailable to identify children who have been exposed to psychosocial stress and the buffers of stress exposure. <h3>Objective</h3> To assess whether a growth mark in tooth enamel, the neonatal line, is associated with exposure to prenatal and perinatal maternal psychosocial factors. <h3>Design, Setting, and Participants</h3> This prospective cohort study used exfoliated primary canine teeth and epidemiological survey data from 70 children enrolled in the Avon Longitudinal Study of Parents and Children, a birth cohort based in Bristol, England. Exfoliated teeth were collected from children at 5 to 7 years of age. Data were collected from January 1, 1991, to December 31, 1998, and were analyzed from January 1, 2019, to August 10, 2021. <h3>Exposures</h3> Four types of prenatal and perinatal maternal psychosocial factors were studied: stressful life events, psychopathological history, neighborhood disadvantage, and social support. Data were collected from mailed-in questionnaires completed during and shortly after pregnancy. <h3>Main Outcomes and Measures</h3> Neonatal line width measured within 3 portions of the tooth crown (the cuspal, middle, and innermost third) in exfoliated primary canines. <h3>Results</h3> A total of 70 children (34 of 70 [48.7%] male; 63 of 67 [94.0%] White) were studied. Most children were born full term (57 [83.8%]) and to mothers of typical child-bearing age (60 [88.2%]). Neonatal lines were wider in the canines of children born to mothers who self-reported severe lifetime depression (β = 3.35; 95% CI, 1.48-5.23;<i>P</i> = .001), any lifetime psychiatric problems (β = 2.66; 95% CI, 0.92-4.41;<i>P</i> = .003), or elevated anxiety or depressive symptoms at 32 weeks' gestation (β = 2.29; 95% CI, 0.38-4.20;<i>P</i> = .02). By contrast, neonatal lines were narrower in children born to mothers who self-reported high social support shortly after birth (β = −2.04; 95% CI, −3.70 to −0.38;<i>P</i> = .02). The magnitude of these associations was large, up to 1.2 SD unit differences, and persisted after adjusting for other risk factors. <h3>Conclusions and Relevance</h3> In this cohort study, neonatal line width was associated with exposure to maternal perinatal psychosocial factors. Replication and validation of these findings can further evaluate teeth as possible new biomarkers.
Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study
Authors: Sumithira Vasu, Meghan Kromer, Qiuhong Zhao, Hannah Choe, Karilyn Larkin, Sarah A Wall, Samantha Jaglowski, Sam Penza, Jonathan E Brammer, Nidhi Sharma, Naduparambil Jacob, Marcos J.G. de Lima, Meng Welliver
Journal: Blood (2021)
Impact of precoding on reimbursement in diagnosis-related group systems: Randomized controlled trial
Authors: Ignazio Tarantino, Bernhard Widmann, Rene Warschkow, Michael Weitzendorfer, Susanne Bock, Sandra Roeske, Fariba Abbassi, Rosita Sortino, Bruno M. Schmied, Thomas Steffen
Journal: International Journal of Surgery (2021)
Role of IL‐18‐transformed CD274‐expressing eosinophils in promoting airway obstruction in experimental asthma
Authors: Anil Mishra, Dewan Majid, Hemanth Kumar Kandikattu, Chandra Sekhar Yadavalli, Sathisha Upparahalli Venkateshaiah
Journal: Allergy (2021)

Abstract Background IL‐5‐dependent residential and IL‐18‐transformed pathogenic eosinophils have been reported; however, the role of IL‐18‐transformed CD274‐expressing pathogenic eosinophils compared to IL‐5‐generated eosinophils in promoting airway obstruction in asthma has not yet been examined. Methods Eosinophils are detected by tissue anti‐MBP and anti‐EPX immunostaining, CD274 expression by flow cytometry, and airway resistance using the Buxco FinePointe RC system. Results We show that A . fumigatus ‐challenged wild‐type mice, and different gene‐deficient mice including naïve CC10‐IL‐18‐transgenic mice, accumulate mostly peribronchial and perivascular CD274‐expressing eosinophils except naïve CD2‐IL‐5‐transgenic mice. Additionally, we show that CD2‐IL‐5 transgenic mice following rIL‐18 treatment accumulate high number of CD274‐expressing perivascular and peribronchial eosinophils with induced collagen, goblet cell hyperplasia and airway resistance compared to saline‐challenged CD2‐IL5 transgenic mice. Furthermore, we also show that even A . fumigatus ‐challenged IL ‐ 5 −/− mice and rIL‐18 given ΔdblGATA mice accumulate CD274‐expressing eosinophil‐associated asthma pathogenesis including airway obstruction. Most importantly, we provide evidence that neutralization of CD274 and IL‐18 in A . fumigatus ‐challenged mice ameliorate experimental asthma. Taken together, the data presented are clinically significant in establishing that anti‐IL‐18 neutralization is a novel immunotherapy to restrict asthma pathogenesis. Conclusions We demonstrate that IL‐18 is critical for inducing asthma pathogenesis, and neutralization of CD274 is a potential immunotherapeutic strategy for asthma.
Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2
Authors: Yiao Jiang, Jiayin Peng, Jiawen Song, Juan He, Man Jiang, Jia Wang, Liya Ma, Yuang Wang, Moubin Lin, Hailong Wu, Zhao Zhang, Dong Gao, Yun Zhao
Journal: Nature Metabolism (2021)
Abstract 12747: The Unique micro-RNA Signature in Amniotic Fluid of Recipients Fetuses With Twin-Twin Transfusion Syndrome Cardiomyopathy
Authors: Eleanor L Schuchardt, Timothy M Crombleholme, Jeannie Zuk, Armin Korst, Anis Karimpour-Fard, Bettina Cuneo, Lisa W Howley, Shelley Miyamoto, Carmen C Sucharov
Journal: Circulation (2018)

Introduction: Twin-twin transfusion syndrome (TTTS) affects 10-15% of monochorionic pregnancies with high morbidity and mortality. Cardiomyopathy affects 70% of early and 100% of advanced TTTS reci...
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Authors: Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John M. Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Jenny J. Kim, Yan Zheng, Rhine R. Shen, Saran Vardhanabhuti, Tom Van Meerten
Journal: Blood (2021)
Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T
Authors: Giulia Cheloni, Eleni Kanata, Dina Stroopinsky, Dimitra Karagkouni, Jessica J. Liegel, Daniela Torres, Joshua Hauser, Poorva Bindal, Anita G. Koshy, Yered Pita-Juarez, Adrian Bot, Mike Mattie, Justin Chou, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos
Journal: Blood (2021)
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease
Authors: A. Hung, S. C. Shah, A. Bick, Z. Yu, H. C. Chen, R. Tao, E. A. Akwo, C. P. Chung, M. E. Matheny, K. Susztak, C. Robinson-Cohen, S. Tuteja, E. D. Siew
Journal: Journal of the American Society of Nephrology (2020)

Mutations in PKD1 and PKD2, which encode the transmembrane proteins polycystin-1 and polycystin-2, respectively, cause autosomal dominant polycystic kidney disease (ADPKD). Polycystins are expressed in the primary cilium, and disrupting cilia structure significantly slows ADPKD progression following inactivation of polycystins. The cellular mechanisms of polycystin- and cilia-dependent cyst progression in ADPKD remain incompletely understood.Unbiased transcriptional profiling in an adult-onset Pkd2 mouse model before cysts formed revealed significant differentially expressed genes (DEGs) in Pkd2 single-knockout kidneys, which were used to identify candidate pathways dysregulated in kidneys destined to form cysts. In vivo studies validated the role of the candidate pathway in the progression of ADPKD. Wild-type and Pkd2/Ift88 double-knockout mice that are protected from cyst growth served as controls.The RNASeq data identified cell proliferation as the most dysregulated pathway, with 15 of 241 DEGs related to cell cycle functions. Cdk1 appeared as a central component in this analysis. Cdk1 expression was similarly dysregulated in Pkd1 models of ADPKD, and conditional inactivation of Cdk1 with Pkd1 markedly improved the cystic phenotype and kidney function compared with inactivation of Pkd1 alone. The Pkd1/Cdk1 double knockout blocked cyst cell proliferation that otherwise accompanied Pkd1 inactivation alone.Dysregulation of Cdk1 is an early driver of cyst cell proliferation in ADPKD due to Pkd1 inactivation. Selective targeting of cyst cell proliferation is an effective means of slowing ADPKD progression caused by inactivation of Pkd1.
Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Authors: Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail
Journal: Blood (2021)
Single Cell Analysis of Adult Human Hematopoietic Stem and Progenitor Cells Identifies a Novel Lymphoid Primed Multipotent Progenitor That Expands in Relapsed Acute Myeloid Leukemia
Authors: Asiri Ediriwickrema, Bogdan A. Luca, Aaron M Newman, Andrew J Gentles, Ravindra Majeti
Journal: Blood (2021)
Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States
Authors: Bijal D. Shah, Keri Yang, Sizhu Liu, Jai Sivanantham, Yasser Ali, Chris Casten, Swaroop Satya, Boxiong Tang
Journal: Blood (2021)
Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma
Authors: Ricardo De Matos Simoes, Benjamin G Barwick, Ryosuke Shirasaki, Olga Dashevsky, Sara Gandolfi, Huihui Tang, Brian Glassner, Richard W.J. Groen, Daniel Auclair, Aedin Culhane, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades
Journal: Blood (2021)
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Authors: Giuseppe Auteri, Vito Sansone, Daniela Bartoletti, Christian Di Pietro, Emanuele Sutto, Camilla Mazzoni, Nicola Vianelli, Michele Cavo, Fabio Piscaglia, Francesca Palandri
Journal: Blood (2021)
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Authors: Weina Yu, Qingyang Lei, Li Yang, Guohui Qin, Shasha Liu, Dan Wang, Yu Ping, Yi Zhang
Journal: Journal of Hematology & Oncology (2021)

Complex interactions between the immune system and tumor cells exist throughout the initiation and development of cancer. Although the immune system eliminates malignantly transformed cells in the early stage, surviving tumor cells evade host immune defense through various methods and even reprogram the anti-tumor immune response to a pro-tumor phenotype to obtain unlimited growth and metastasis. The high proliferation rate of tumor cells increases the demand for local nutrients and oxygen. Poorly organized vessels can barely satisfy this requirement, which results in an acidic, hypoxic, and glucose-deficient tumor microenvironment. As a result, lipids in the tumor microenvironment are activated and utilized as a primary source of energy and critical regulators in both tumor cells and related immune cells. However, the exact role of lipid metabolism reprogramming in tumor immune response remains unclear. A comprehensive understanding of lipid metabolism dysfunction in the tumor microenvironment and its dual effects on the immune response is critical for mapping the detailed landscape of tumor immunology and developing specific treatments for cancer patients. In this review, we have focused on the dysregulation of lipid metabolism in the tumor microenvironment and have discussed its contradictory roles in the tumor immune response. In addition, we have summarized the current therapeutic strategies targeting lipid metabolism in tumor immunotherapy. This review provides a comprehensive summary of lipid metabolism in the tumor immune response.
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study
Authors: Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood (2021)
Corticosteroid Treatment Impairs Epithelial Regeneration, Limiting Intestinal Recovery in Experimental Graft Vs Host Disease
Authors: Viktor Arnhold, Suze A Jansen, Winston Chang, Govindarajan Thangavelu, Paola Vinci, Shuichiro Takashima, Anastasiya Egorova, Jason Kuttiyara, Marliek van Hoesel, Chen Liu, Marco Calafiore, Bruce R. Blazar, Caroline Lindemans, Alan M Hanash
Journal: Blood (2021)